Understanding the patient's lived experience of neovascular age-related macular degeneration: A qualitative study

Eye (Basingstoke)

Volumn 29, Issue 12, 2015, Pages 1561-1569

  McCloud, C ^a   Lake, S ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LANTHANUM; RANIBIZUMAB; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DISABILITY; EXPERIENCE; FEMALE; HUMAN; INTERVIEW; LIFESTYLE; MALE; OPTIMISM; PATIENT CARE; PERCEPTION; PERSONAL EXPERIENCE; QUALITATIVE ANALYSIS; TREATMENT DURATION; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PSYCHOLOGY; QUALITATIVE RESEARCH; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; QUALITATIVE RESEARCH; QUALITY OF LIFE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SICKNESS IMPACT PROFILE; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84949604744     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.167     Document Type: Article

References (28)

1. Wang JJ, Rochtchina E, Lee AJ, Chia E-M, Smith W, Cumming RG et al. Ten-year incidence and progression of age-related maculopathy: the blue mountains eye study. Ophthalmology 2007; 114(1): 92-98.
2. Guymer R, Chong E. Modifiable risk factors for age-related macular degeneration. Med J Aust 2006; 184(9): 455-458.
3. Tomany SC, Wang JJ, van Leeuwen R, Klein R, Mitchell P, Vingerling JR et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004; 111(7): 1280-1287.
4. Baird PN, Chakrabarti S. How genetic studies have advanced our understanding of age-related macular degeneration and their impact on patient care: a review. Clin Experiment Ophthalmol 2014; 42(1): 53-64.
5. Mitchell J, Bradley C. Quality of Life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006; 4: 97.
6. Comer GM, Ciulla TA, Criswell MH, Tolentino M. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004; 21(15): 967-992.
7. Brown G, Brown MM. Let us wake the nation on the treatment for age-related macular degeneration. Curr Opin Ophthalmol 2010; 21(3): 169-171.
8. Frampton J. Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging 2013; 30(5): 331-358.
9. Hasson M. Anti-VEGF agents have sparked swift, dramatic changes in wet AMD treatment. Ocul Surg News 2007; 25(20): 6-8.
10. Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2012; 23(3): 182-188.
11. Caire J, Recalde S, Velazquez-Villoria A, Garcia-Garcia L, Reiter N, Anter J et al. Growth of geographic atrophy on fundus autofluorescence and polymorphisms of cfh, cfb, c3, fhr1-3, and arms2 in age-related macular degeneration. JAMA Ophthalmol 2014; 132(5): 528-534.
12. McCloud C, Khadka J, Gilhotra JS, Pesudovs K. Divergence in the lived experience of people with macular degeneration. Optom Vis Sci 2014; 91(8): 966-974.
13. Heywood D, Stronach I. Philosophy and hermeneutics In: Somekh B, Lewin C (eds). Research Methods in the Social Sciences. Sage Publications: London, UK, 2005, pp 114-120.
14. Hunt K, Lathleen J. Sampling. In: Gerrish K, Lathlean J (eds). The Research Process in Nursing, 7th ed. Wiley Blackwell: Chichester, UK, 2015, pp 173-184.
15. Lathlean J. Qualitative Analysis. In: Gerrish K, Lathlean J (eds). The Research process in Nursing, 7th ed. Wiley Blackwell: Chichester, UK, 2015, pp 469-487.
16. Bennion AE, Shaw RL, Gibson JM. What do we know about the experience of age related macular degeneration? A systematic review and meta-synthesis of qualitative research. Soc Sci Med 2012; 75(6): 976-985.
17. Owsley C, McGwin Jr G, Scilley K, Dreer LE, Bray CR, Mason III JO. Focus groups with persons who have age-related macular degeneration: emotional issues. Rehabil Psychol 2006; 51(1): 23-29.
18. Casten R, Rovner B. Depression in age-related macular degeneration. J Vis Impair Blind 2008; 102(10): 591-599.
19. Burton AE, Shaw R, Gibson J. Experiences of patients with age-related macular degeneration receiving anti-vascular endothelial growth factor therapy: a qualitative study. Br J Vis Imp 2013; 31(3): 178-188.
20. Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C. Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. Psychol Health Med 2014; 20(3): 296-310.
21. Titchen A, Hobson D. Phenomenology In: Somekh B, Lewin C (eds). Research Methods in the Social Sciences. Sage Publications: London, UK, 2005, pp 121-130.
22. Galvin K, Holloway I, Phenomenological research In: Gerrish K, Lathlean J (eds). The Research Process in Nursing. Wily Blackwell: West Sussex, UK, 2015, pp 211-223.
23. Droege K, Caramoy A, Kersten A, Luberichs-Fauser J, Zilkens K, Müller D et al. Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration-monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol 2014; 252(1): 31-34.
24. Creswell J. Research design: Quantitative and Mixed methods Approaches, 4th ed. Sage: Thousand Oaks, CA, USA, 2014.
25. Polit D, Beck C. Nursing Research: Generating and Assessing Evidence for Nursing Practice, 9th ed. Wolters Kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2012, p800.
26. Taylor H, Keeffe J, Vu HTV, Wang J, Rochtchina E, Pezzullo ML et al. Vision loss in Australia. Med J Aust 2005; 182(11): 565-568.
27. Cimberle M. AMD vision loss hurts quality of life: AREDS. Ocul Surg News 2002; 20(23): 1.
28. Owsley C, McGwin G. Measuring the personal burden of eye disease and vision impairment. Ophthalmic Epidemiol 2007; 14(4): 188-191.